{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:13:24Z","timestamp":1768443204221,"version":"3.49.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T00:00:00Z","timestamp":1090800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T00:00:00Z","timestamp":1090800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,9,1]]},"DOI":"10.1038\/sj.bmt.1704604","type":"journal-article","created":{"date-parts":[[2004,7,26]],"date-time":"2004-07-26T09:05:34Z","timestamp":1090832734000},"page":"471-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation"],"prefix":"10.1038","volume":"34","author":[{"given":"C","family":"Cutler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Antin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,7,26]]},"reference":[{"key":"BF1704604_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729\u2013735.","journal-title":"N Engl J Med"},{"key":"BF1704604_CR2","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1016\/S0041-1345(03)00230-6","volume":"35","author":"RA Kirken","year":"2003","unstructured":"Kirken RA, Wang YL . Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc 2003; 35: S227\u2013S230.","journal-title":"Transplant Proc"},{"key":"BF1704604_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1182\/blood.V100.3.1084","volume":"100","author":"H Hackstein","year":"2002","unstructured":"Hackstein H, Taner T, Logar AJ, Thomson AW . Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084\u20131087.","journal-title":"Blood"},{"key":"BF1704604_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007890-200301150-00025","volume":"75","author":"P Monti","year":"2003","unstructured":"Monti P, Mercalli A, Leone BE et al. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75: 137\u2013145.","journal-title":"Transplantation"},{"key":"BF1704604_CR5","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1182\/blood-2002-11-3370","volume":"101","author":"H Hackstein","year":"2003","unstructured":"Hackstein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457\u20134463.","journal-title":"Blood"},{"key":"BF1704604_CR6","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/S0041-1345(02)02900-7","volume":"34","author":"PH Chiang","year":"2002","unstructured":"Chiang PH, Wang L, Liang Y et al. Inhibition of IL-12 signaling Stat4\/IFN-gamma pathway by rapamycin is associated with impaired dendritic (correction of dendritc) cell function. Transplant Proc 2002; 34: 1394\u20131395.","journal-title":"Transplant Proc"},{"key":"BF1704604_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1182\/blood.V98.1.174","volume":"98","author":"AM Woltman","year":"2001","unstructured":"Woltman AM, de Fijter JW, Kamerling SW et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174\u2013180.","journal-title":"Blood"},{"key":"BF1704604_CR8","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood-2002-06-1688","volume":"101","author":"AM Woltman","year":"2003","unstructured":"Woltman AM, van der Kooij SW, Coffer PJ et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439\u20131445.","journal-title":"Blood"},{"key":"BF1704604_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","volume":"71","author":"AS MacDonald","year":"2001","unstructured":"MacDonald AS . A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271\u2013280.","journal-title":"Transplantation"},{"key":"BF1704604_CR10","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1097\/01.TP.0000071301.86299.75","volume":"75","author":"JP van Hooff","year":"2003","unstructured":"van Hooff JP, Squifflet JP, Wlodarczyk Z et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 1934\u20131939.","journal-title":"Transplantation"},{"key":"BF1704604_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","volume":"74","author":"SM Flechner","year":"2002","unstructured":"Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070\u20131076.","journal-title":"Transplantation"},{"key":"BF1704604_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/jlts.2003.50183","volume":"9","author":"KD Fairbanks","year":"2003","unstructured":"Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ . Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079\u20131085.","journal-title":"Liver Transpl"},{"key":"BF1704604_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/jlts.2003.50026","volume":"9","author":"S Nair","year":"2003","unstructured":"Nair S, Eason J, Loss G . Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003; 9: 126\u2013129.","journal-title":"Liver Transpl"},{"issue":"Suppl. 7","key":"BF1704604_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1034\/j.1399-0012.16.s7.7.x","volume":"16","author":"AH Cotterell","year":"2002","unstructured":"Cotterell AH, Fisher RA, King AL et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002; 16 (Suppl. 7): 49\u201351.","journal-title":"Clin Transplant"},{"key":"BF1704604_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0140-6736(99)03882-9","volume":"355","author":"VC McAlister","year":"2000","unstructured":"McAlister VC, Gao Z, Peltekian K et al. Sirolimus\u2013tacrolimus combination immunosuppression. Lancet 2000; 355: 376\u2013377.","journal-title":"Lancet"},{"key":"BF1704604_CR16","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1097\/01.TP.0000053752.87383.67","volume":"75","author":"H Koenen","year":"2003","unstructured":"Koenen H, Michielsen E, Verstappen J et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation 2003; 75: 1581\u20131590.","journal-title":"Transplantation"},{"key":"BF1704604_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","volume":"77","author":"G Ciancio","year":"2004","unstructured":"Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation.I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244\u2013251.","journal-title":"Transplantation"},{"key":"BF1704604_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","volume":"77","author":"G Ciancio","year":"2004","unstructured":"Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252\u2013258.","journal-title":"Transplantation"},{"key":"BF1704604_CR19","doi-asserted-by":"publisher","first-page":"209S","DOI":"10.1016\/S0041-1345(03)00217-3","volume":"35","author":"GW Neff","year":"2003","unstructured":"Neff GW, Montalbano M, Tzakis AG . Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35: 209S\u2013216S.","journal-title":"Transplant Proc"},{"key":"BF1704604_CR20","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","volume":"72","author":"AI Benito","year":"2001","unstructured":"Benito AI, Furlong T, Martin PJ et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924\u20131929.","journal-title":"Transplantation"},{"key":"BF1704604_CR21","first-page":"87","volume":"8","author":"L Johnston","year":"2002","unstructured":"Johnston L, Shizuru J, Stockerl-Goldstein K et al. Rapamycin for treatment of chronic graft versus host disease. Biol Blood Marrow Transplant 2002; 8: 87 (abstract).","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704604_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1083-8791(03)80016-2","volume":"9","author":"D Couriel","year":"2003","unstructured":"Couriel D, Hicks K, Saliba R et al. Sirolimus (rapamycin) for treatment of steroid-refractory chronic graft versus host disease. Biol Blood Marrow Transplant 2003; 9: 67 (abstract).","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704604_CR23","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1182\/blood-2003-02-0489","volume":"102","author":"JH Antin","year":"2003","unstructured":"Antin JH, Kim HT, Cutler C et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601\u20131605.","journal-title":"Blood"},{"key":"BF1704604_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","volume":"10","author":"C Cutler","year":"2004","unstructured":"Cutler C, Kim HT, Hochberg EP et al. Sirolimus and tacrolimus without methotrexate as graft-vs host disease prophylaxis after matched, related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 328\u2013336.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704604_CR25","first-page":"711a","volume":"102","author":"E Alyea","year":"2003","unstructured":"Alyea E, Neuberg D, Cutler C et al. Sirolimus, tacrolimus and low dose methotrexate as graft versus host disease prophylaxis after matched related and unrelated nonmyeloablative transplantation is well tolerated and associated with a low incidence of acute GVHD. Blood 2003; 102: 711a (abstract).","journal-title":"Blood"},{"key":"BF1704604_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bbmt.2003.12.182","volume":"10","author":"DF Claxton","year":"2004","unstructured":"Claxton DF, Popescu D, Carraher M et al. Sirolimus and tacrolimus allow engraftment of haploidentical and other alternative donor stem cells after non-myeloablative conditioning. Biol Blood Marrow Transplant 2004; 10: 38\u201339 (abstract).","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1704604_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jca.10030","volume":"17","author":"BC McLeod","year":"2002","unstructured":"McLeod BC . Thrombotic microangiopathies in bone marrow and organ transplant patients. J Clin Apheresis 2002; 17: 118\u2013123.","journal-title":"J Clin Apheresis"},{"key":"BF1704604_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","volume":"44","author":"JN George","year":"2004","unstructured":"George JN, Li X, McMinn JR et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294\u2013304.","journal-title":"Transfusion"},{"key":"BF1704604_CR29","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/00007890-200203150-00017","volume":"73","author":"RM Langer","year":"2002","unstructured":"Langer RM, Van Buren CT, Katz SM, Kahan BD . De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine\u2013sirolimus combination. Transplantation 2002; 73: 756\u2013760.","journal-title":"Transplantation"},{"key":"BF1704604_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/01.TP.0000092522.36410.D0","volume":"77","author":"AS Paramesh","year":"2004","unstructured":"Paramesh AS, Grosskreutz C, Florman SS et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004; 77: 129\u2013131.","journal-title":"Transplantation"},{"key":"BF1704604_CR31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1600-6143.2003.00051.x","volume":"3","author":"M Robson","year":"2003","unstructured":"Robson M, Cote I, Abbs I et al. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324\u2013327.","journal-title":"Am J Transplant"},{"key":"BF1704604_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1034\/j.1600-6143.2003.00018.x","volume":"3","author":"JA Saikali","year":"2003","unstructured":"Saikali JA, Truong LD, Suki WN . Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3: 229\u2013230.","journal-title":"Am J Transplant"},{"key":"BF1704604_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0272-6386(03)00424-4","volume":"42","author":"G Barone","year":"2003","unstructured":"Barone G, Gurley B, Abul-Ezz S, G\u00f6kden N . Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003; 42: 202\u2013206.","journal-title":"Am J Kidney Dis"},{"key":"BF1704604_CR34","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/ndt\/17.8.1524","volume":"17","author":"C Edwards","year":"2002","unstructured":"Edwards C, House A, Shahinian V, Knoll G . Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 2002; 17: 1524\u20131526.","journal-title":"Nephrol Dial Transplant"},{"key":"BF1704604_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1159\/000057626","volume":"91","author":"P Heering","year":"2002","unstructured":"Heering P, Deppe CE, Farokhzad F et al. Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with rapamycin. Nephron 2002; 91: 177.","journal-title":"Nephron"},{"key":"BF1704604_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5414\/CNP58077","volume":"58","author":"A Yango","year":"2002","unstructured":"Yango A, Morrissey P, Monaco A et al. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol 2002; 58: 77\u201378.","journal-title":"Clin Nephrol"},{"key":"BF1704604_CR37","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1016\/S0041-1345(02)03511-X","volume":"34","author":"VD Garcia","year":"2002","unstructured":"Garcia VD, Bonamigo-Filho JS, Neumann J et al. Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases. Transplant Proc 2002; 34: 2993\u20132995.","journal-title":"Transplant Proc"},{"key":"BF1704604_CR38","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","volume":"75","author":"M Majewski","year":"2003","unstructured":"Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710\u20131717.","journal-title":"Transplantation"},{"key":"BF1704604_CR39","first-page":"4472","volume":"63","author":"RR Nepomuceno","year":"2003","unstructured":"Nepomuceno RR, Balatoni CE, Natkunam Y et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472\u20134480.","journal-title":"Cancer Res"},{"key":"BF1704604_CR40","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.1128\/JVI.75.13.6022-6032.2001","volume":"75","author":"RA Johnson","year":"2001","unstructured":"Johnson RA, Wang X, Ma XL et al. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol 2001; 75: 6022\u20136032.","journal-title":"J Virol"},{"key":"BF1704604_CR41","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1128\/JVI.76.8.3731-3738.2002","volume":"76","author":"Y Yu","year":"2002","unstructured":"Yu Y, Alwine JC . Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3'-OH kinase pathway and the cellular kinase Akt. J Virol 2002; 76: 3731\u20133738.","journal-title":"J Virol"},{"key":"BF1704604_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.transproceed.2003.11.039","volume":"36","author":"BD Kahan","year":"2004","unstructured":"Kahan BD . Sirolimus: a ten-year perspective. Transplant Proc 2004; 36: 71\u201375.","journal-title":"Transplant Proc"},{"key":"BF1704604_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1399-3062.2003.00032.x","volume":"5","author":"JF Trotter","year":"2003","unstructured":"Trotter JF, Wallack A, Steinberg T . Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transplant Infect Dis 2003; 5: 174\u2013180.","journal-title":"Transplant Infect Dis"},{"key":"BF1704604_CR44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909\u2013918.","journal-title":"J Clin Oncol"},{"key":"BF1704604_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1677\/erc.0.0080249","volume":"8","author":"K Yu","year":"2001","unstructured":"Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249\u2013258.","journal-title":"Endocr Relat Cancer"},{"key":"BF1704604_CR46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3816\/CBC.2003.n.018","volume":"4","author":"MM Mita","year":"2003","unstructured":"Mita MM, Mita A, Rowinsky EK . Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126\u2013137.","journal-title":"Clin Breast Cancer"},{"key":"BF1704604_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/annonc\/mdg248","volume":"14","author":"CJ Punt","year":"2003","unstructured":"Punt CJ, Boni J, Bruntsch U et al. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003; 14: 931\u2013937.","journal-title":"Ann Oncol"},{"key":"BF1704604_CR48","first-page":"1527","volume":"61","author":"B Geoerger","year":"2001","unstructured":"Geoerger B, Kerr K, Tang CB et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527\u20131532.","journal-title":"Cancer Res"},{"key":"BF1704604_CR49","first-page":"886","volume":"59","author":"H Hosoi","year":"1999","unstructured":"Hosoi H, Dilling MB, Shikata T et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999; 59: 886\u2013894.","journal-title":"Cancer Res"},{"key":"BF1704604_CR50","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","volume":"63","author":"FL Luan","year":"2003","unstructured":"Luan FL, Ding R, Sharma VK et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917\u2013926.","journal-title":"Kidney Int"},{"key":"BF1704604_CR51","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1038\/sj.onc.1207081","volume":"22","author":"S Mateo-Lozano","year":"2003","unstructured":"Mateo-Lozano S, Tirado OM, Notario V . Rapamycin induces the fusion-type independent downregulation of the EWS\/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003; 22: 9282\u20139287.","journal-title":"Oncogene"},{"key":"BF1704604_CR52","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cncr.20026","volume":"100","author":"A Panwalkar","year":"2004","unstructured":"Panwalkar A, Verstovsek S, Giles FJ . Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657\u2013666.","journal-title":"Cancer"},{"key":"BF1704604_CR53","doi-asserted-by":"publisher","first-page":"15113","DOI":"10.1073\/pnas.2436348100","volume":"100","author":"VI Brown","year":"2003","unstructured":"Brown VI, Fang J, Alcorn K et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113\u201315118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1704604_CR54","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1182\/blood-2002-01-0189","volume":"101","author":"T Decker","year":"2003","unstructured":"Decker T, Hipp S, Ringshausen I et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101: 278\u2013285.","journal-title":"Blood"},{"key":"BF1704604_CR55","first-page":"5716","volume":"63","author":"C Ly","year":"2003","unstructured":"Ly C, Arechiga AF, Melo JV et al. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63: 5716\u20135722.","journal-title":"Cancer Res"},{"key":"BF1704604_CR56","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","volume":"100","author":"M Mayerhofer","year":"2002","unstructured":"Mayerhofer M, Valent P, Sperr WR et al. BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002; 100: 3767\u20133775.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704604","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:45:20Z","timestamp":1648079120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,26]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,9,1]]}},"alternative-id":["BF1704604"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704604","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,26]]},"assertion":[{"value":"26 July 2004","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}